Skip to content
value.today

Aminex Therapeutics, Inc.

Total raised
$31 M
4 rounds on record
Latest round
$15 M
Oct 2022
First round on record
Jun 2014
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Aminex Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2022$15 MNo. 4$10 to $50 million

Aminex Therapeutics, Inc.: Raise no. 4, Oct 2022

Investors in this round

162 investors had bought by the notice of Dec 5, 2025: 162 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $30 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Washington

People named in the notice

  • Mark Burns · Executive Officer, Director
  • David Meeks · Director
  • Deyaa Adib · Director
  • Don Dyer · Director
  • James Skaggs · Director
  • Jeffrey Miller · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Meek, Executive Chairman. Source: SEC Form D, newest notice filed Dec 5, 2025. Read the notice at the SEC.

equitySEC
Aug 2021$6 MNo. 3$2 to $10 million

Aminex Therapeutics, Inc.: Raise no. 3, Aug 2021

Investors in this round

97 investors had bought by the notice of Aug 19, 2021: 97 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $9 M offered; $3 M still to sell
Smallest investment taken
$2
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Washington

People named in the notice

  • James Skaggs · Executive Officer, Director
  • Larry Richards · Executive Officer
  • Mark Burns · Executive Officer, Director
  • Jeff Miller · Director
  • Rhonda Rhyne · Director
  • Roger Ulrich · Director
  • Stacy Hock · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “$3,141,549 pursuant to conversion of convertible promissory notes, remaining $3,156.955 issued pursuant to cash investment.”

Signed by James B. Skaggs, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 19, 2021. Read the notice at the SEC.

equitySEC
May 2018$8 MNo. 2$2 to $10 million

Aminex Therapeutics, Inc.: Raise no. 2, May 2018

Investors in this round

96 investors had bought by the notice of Jun 1, 2018: 96 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $14 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Washington

People named in the notice

  • James Skaggs · Executive Officer, Director
  • Mark Burns · Executive Officer, Director
  • Thomas Graham · Executive Officer, Director
  • Jeff Miller · Director
  • Rhonda Rhyne · Director
  • Roger Ulrich · Director
  • Stacy Hock · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas Graham, Chief Operating Officer. Source: SEC Form D, newest notice filed Jun 1, 2018. Read the notice at the SEC.

equitySEC
Jun 2014$2 MNo. 1Under $2 million

Aminex Therapeutics, Inc.: Raise no. 1, Jun 2014

Investors in this round

22 investors had bought by the notice of Jul 11, 2014: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Washington

People named in the notice

  • James Skaggs · Executive Officer, Director
  • Mark Burns · Executive Officer, Director
  • Thomas Graham · Executive Officer, Director
  • Donald Mowat · Director
  • John Rosling · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas Graham, Coo. Source: SEC Form D, newest notice filed Jul 11, 2014. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Aminex Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2025).

    SEC Form D · Dec 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2025

That is all the official record says: Aminex Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Aminex Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 162 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Aminex Therapeutics, Inc.
NameRoleNamed in
Mark BurnsExecutive officerDec 2025
James SkaggsExecutive officerAug 2021
Larry RichardsExecutive officerAug 2021
Thomas GrahamExecutive officerJun 2018
David MeeksDirectorDec 2025
Deyaa AdibDirectorDec 2025
Don DyerDirectorDec 2025
James SkaggsDirectorDec 2025
Jeffrey MillerDirectorDec 2025
Mark BurnsDirectorDec 2025
Jeff MillerDirectorAug 2021
Rhonda RhyneDirectorAug 2021
Roger UlrichDirectorAug 2021
Stacy HockDirectorAug 2021
Thomas GrahamDirectorJun 2018
Donald MowatDirectorJul 2014
John RoslingDirectorJul 2014